The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
Open accessAbstract
Background Change in albuminuria has strong biological plausibility as a surrogate endpoint for progression of chronic kidney disease, but empirical evidence to support its validity is lacking. We aimed to determine the association between treatment effects on early changes in albuminuria and treatment effects on clinical endpoints and surrograte endpoints, to inform the use of albuminuria as a surrogate endpoint in future randomised controlled trials. Methods In this meta-analysis, we searched PubMed for publications in English from Jan 1, 1946, to Dec 15, 2016, using search terms including "chronic kidney disease", "chronic renal insufficiency", "albuminuria", "proteinuria", and "randomized controlled trial"; key inclusion criteria were quantifiable measurements of albuminuria or proteinuria at baseline and within 12 months of follow-up and information on the incidence of end-stage kidney disease. We requested use of individual patient data from the authors of eligible studies. For all studies that the authors agreed to participate and that had sufficient data, we estimated treatment effects on 6-month change in albuminuria and the composite clinical endpoint of treated end-stage kidney disease, estimated glomerular filtration rate of less than 15 mL/min per 1·73 m 2 , or doubling of serum creatinine. We used a Bayesian mixed-effects meta-regression analysis to relate the treatment effects on albuminuria to those on the clinical endpoint across studies and developed a prediction model for the treatment effect on the clinical endpoint on the basis of the treatment effect on albuminuria. Findings We identified 41 eligible treatment comparisons from randomised trials (referred to as studies) that provided sufficient patient-level data on 29 979 participants (21 206 [71%] with diabetes). Over a median follow-up of 3·4 years (IQR 2·3–4·2), 3935 (13%) participants reached the composite clinical endpoint. Across all studies, with a meta-regression slope of 0·89 (95% Bayesian credible interval [BCI] 0·13–1·70), each 30% decrease in geometric mean albuminuria by the treatment relative to the control was associated with an average 27% lower hazard for the clinical endpoint (95% BCI 5–45%; median R 2 0·47, 95% BCI 0·02–0·96). The association strengthened after restricting analyses to patients with baseline albuminuria of more than 30 mg/g (ie, 3·4 mg/mmol; R 2 0·72, 0·05–0·99]). For future trials, the model predicts that treatments that decrease the geometric mean albuminuria to 0·7 (ie, 30% decrease in albuminuria) relative to the control will provide an average hazard ratio (HR) for the clinical endpoint of 0·68, and 95% of sufficiently large studies would have HRs between 0·47 and 0·95. Interpretation Our results support a role for change in albuminuria as a surrogate endpoint for the progression of chronic kidney disease, particularly in patients with high baseline albuminuria; for patients with low baseline levels of albuminuria this association is less certain. Funding US National Kidney Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, although the magnitude of the percentage reduction in albuminuria observed with retatrutide treatment is associated with long-term kidney function preservation in previous trials, the absolute reduction in albuminuria was modest because the majority of patients had normal albuminuria.”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The 32% reduction in UACR observed with retatrutide in participants with T2D may be clinically relevant because treatments that reduce albuminuria by > 30% are associated with a high likelihood to reduce the risk of clinical kidney outcomes.24”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“These effects are clinically relevant because therapies that reduce albuminuria by 25–30% are likely to confer significant benefits in reducing the risk of long-term clinical kidney outcomes (27,28).”
The cited source says what the claim attributes to it.
In the citing paper
“Post hoc analyses of randomized trials and observational cohorts have demonstrated that an initial larger albuminuria reduction is associated with better long-term outcomes.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [56]
In the citing paper
“Therefore, despite the clear relative risk reductions in kidney disease outcomes, the observed absolute risk reductions were modest with relatively higher NNT than that reported in the dedicated kidney disease outcomes trials of SGLT2 inhibitors. 44”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Self-citationEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationKDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Self-citationde Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Self-citationHow Does Proteinuria Cause Progressive Renal Damage?
Abbate, M., Zoja, C., & Remuzzi, G. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006040377 · Cited by 779
Self-citationEfficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053107 · Cited by 710
Self-citationLevey, A. S., Inker, L. A., Matsushita, K., Greene, T., Willis, K., Lewis, E., de Zeeuw, D., Cheung, A. K., & Coresh, J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.030 · Cited by 620
Self-citationRuggenenti, P., Nefrologia”(GISEN), O. B. O. T. “. I. D. S. E. I., Perna, A., Mosconi, L., Pisoni, R., & Remuzzi, G. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00874.x · Cited by 434
Self-citationBlood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system
(2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3280bad9b4 · Cited by 414
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationKDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citationKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citationHeerspink, H. J. L., Parving, H.-H., Andress, D. L., Bakris, G., Correa-Rotter, R., Hou, F.-F., Kitzman, D. W., Kohan, D., Makino, H., McMurray, J. J. V., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30772-x · Cited by 628
Self-citationPathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00393-8 · Cited by 589
Metadata
- Authors
- Heerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., Praga, M., Schena, F. P., Levey, A. S., Inker, L. A., Sevillano, A., Kamper, A.-L., van Zuilen, A. D., Brenner, B. M., Maes, B., Ihle, B. U., Barret, B., Leung, C., Szeto, C., Fitzner, C., Wanner, C., Pozzi, C., Montagnino, C. P., Xie, D., de Zeeuw, D., Lewis, E., Verde, E., Gutierrez, E., Imai, E., Hou, F. F., Caravaca, F., Fervenza, F. C., Locatelli, F., Schena, F. P., Kobayashi, F., Moroni, G., Becker, G. J., Beck, G. J., Appel, G. B., Frisch, G., van Essen, G., Maschio, G., Remuzzi, G., Montogrino, G., Parving, H.-H., Heerspink, H. J. L., Makino, H., Jehan, I., Wetzels, J. F. M., Donadio, J., Dwyer, J., van den Brand, J., Kusek, J., Lachin, J. M., Luño, J., Lewis, J. B., Floege, J., Abebe, K. Z., Chow, K., Hunsicker, L. G., del Vecchio, L., Carlo, M., Praga, M., Goicoechea, M., von Eynatten, M., Poulter, N., Chaturvedi, N., Passerini, P., de Jong, P. E., Blankestijn, P. J., Li, P., Ruggenenti, P., Zucchelli, P., Kincaid-Smith, P. S., Hilgers, R.-D., Estacio, R. O., Rohde, R. D., Katafuchi, R., Toto, R. D., Schrier, R. W., Rodby, R. A., Perrone, R. D., Ito, S., Klahr, S., Andrulli, S., Strandgaard, S., Chan, T. M., Hannedouche, T. P., Rauen, T., Greene, T., Verdalles, U., Perkovic, V., & Keane, W.
- Affiliations
- Tufts University (US)
- University Medical Center Groningen (NL)
- Johns Hopkins University (US)
- Tufts Medical Center (US)
- Vanderbilt University (US)
- Queen Mary Hospital (CN)
- Alessandro Manzoni Hospital (IT)
- Corresponding author
- Inker, Lesley A
- ORCID
- Tighiouart, Hocine
- Gansevoort, Ron T
- Coresh, Josef
- Simon, Andrew L
- Levey, Andrew S
- Inker, Lesley A
- Kamper, Anne-Lise
- Maes, Bart
- Fitzner, Christina
- Wanner, Christoph
- Xie, Di
- Lewis, Edmund
- Verde, Eduardo
- Imai, Enyu
- Fervenza, Fernando C.
- Moroni, Gabriella
- Beck, Gerald J.
- Maschio, Giuseppe
- Remuzzi, Giuseppe
- Makino, Hirofumi
- Wetzels, Jack F.M.
- Dwyer, Jamie
- Lachin, John M.
- Floege, Jürgen
- Abebe, Kaleab Z.
- Chow, KM
- Poulter, Neil
- Chaturvedi, Nish
- Blankestijn, Peter J.
- Li, Philip
- Ruggenenti, Piero
- Hilgers, Ralf-Dieter
- Estacio, Raymond O.
- Katafuchi, Ritsuko
- Toto, Robert D.
- Rodby, Roger A.
- Perrone, Ronald D.
- Ito, Sadayoshi
- Andrulli, Simeone
- Hannedouche, Thierry P.
- Rauen, Thomas
- Perkovic, Vlado
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 7
- Issue
- 2
- Pages
- 128-139
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2908535040
- Cited by
- 397
- References
- 28
- Citations by year
- 2026: 64 · 2025: 62 · 2024: 48 · 2023: 53 · 2022: 44 · 2021: 45 · 2020: 43 · 2019: 37
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (acceptedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- National Kidney Foundation
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- albuminuria, surrogate endpoints, chronic kidney disease progression, end-stage renal disease, proteinuria, individual patient data, diabetes mellitus, glomerular filtration rate decline, serum creatinine doubling
- MeSH terms
- Albuminuria, Humans, Kidney Diseases, Prognosis, Risk Factors, Randomized Controlled Trials as Topic, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. https://app.cochat.ai/papers/10.1016/s2213-8587(18)30314-0
- The paper
- Heerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., Praga, M., Schena, F. P., Levey, A. S., Inker, L. A., Sevillano, A., Kamper, A.-L., van Zuilen, A. D., Brenner, B. M., Maes, B., . . . Keane, W. (2019). Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(18)30314-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.